Related Experiment Video
Updated: Jun 5, 2025

The Double-H Maze: A Robust Behavioral Test for Learning and Memory in Rodents
Published on: July 8, 2015
Cognitive impairment predicts medication discrepancies in Huntington's Disease: patient self-report compared to
Stephanie Feleus1,2, Mai-Ly T D Vo3, Laura C M Kuijper4
1Department of Neurology, Leiden University Medical Center, PO 9600, 2300RC, Leiden, The Netherlands. s.feleus@lumc.nl.
Background:
Proper medication reconciliation (= comparing the accuracy of patient-reported medication use with pharmacy records) could prevent potentially dangerous situations such as drug-drug interactions and hospitalization. This is particularly important when patients rely on multiple medications, such as in neurodegenerative disorders like Huntington's Disease (HD). Currently, it is unknown how often medication discrepancies occur in HD patients and which factors contribute to the discrepancies.
Objective:
Identify prognostic factors of medication discrepancies in HD, using patient-reported medication use and local pharmacy records.
Methods:
With 134 pre- and manifest HD patients, we performed a multivariable logistic regression analysis with medication discrepancy as dependent variable (pharmacy records as reference value) and sex, CAP score, disease status (pre- or manifest HD), number of concomitant medications taken, presence of an informal caregiver, Unified Huntington's Disease Rating Scale-Total Functioning Capacity, unified cognitive Z-score and Problem Behaviors Assessment-short characteristic scores for depression, anxiety, and apathy as independent variables.
Results:
Medication discrepancies were reported frequently, both in premanifest (43.2%) and manifest HD subjects (36.7%). Impaired cognition significantly predicted medication discrepancies (beta = -0.688, SE 0.27, p = 0.011). All other variables were non-significant.
Conclusions:
Regardless of HD disease status and stage, patient self-reported medication use is not a reliable source, especially in those with impaired cognitive function. The presence of an informal caregiver and the absence of polypharmacy, depression, anxiety and apathy do not influence self-reported medication accuracy. Objective verification of medication use with HD patients' local pharmacy is recommended.
Trial Registration Number:
ICTRP-NL-OMON55123, HD-med, registered 26-Nov-2019.
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Drug Therapy
Antianxiety Medications
Alzheimer's Disease: Treatment
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Dementia
The progression of dementia is generally gradual....

